U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR 60 (40): 1391-1392.

Superseded Public Domain
File Language:
English


Details

  • Journal Article:
    Morbidity and Mortality Weekly Report (MMWR)
  • Corporate Authors:
  • Description:
    In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months (1). Vaccination with meningococcal polysaccharide vaccine (MPSV4) is not recommended for children aged <2 years because of low immunogenicity and short duration of protection in this age group (2). The Advisory Committee on Immunization Practices (ACIP) Meningococcal Vaccine Work Group reviewed data from four clinical studies on the safety and immunogenicity of MenACWY-D in healthy children aged 9 through 23 months. The pivotal immunogenicity study was a Phase III, multicenter, U.S. trial measuring seroresponse 30 days after 2 doses of MenACWY-D. Antibody titers were measured using a serum bactericidal assay containing human complement (hSBA). Seroresponse was defined as the proportion of subjects with hSBA titers of ?1:8, the accepted measure of protection. The first dose of MenACWY-D was administered alone at age 9 months, followed by a second dose administered alone (n = 404) or concomitantly with measles, mumps, rubella, and varicella vaccine (n = 302) or 7-valent pneumococcal conjugate vaccine (PCV7) (n = 422) at age 12 months. The percentage of subjects with hSBA titers ?1:8 was >90% for all meningococcal serogroups except serogroup W135 (>80%) (3).
  • Subjects:
  • Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(40):1391-2.
  • Series:
  • ISSN:
    0149-2195 (print) ; 1545-861X (digital)
  • Pubmed ID:
    21993344
  • Document Type:
  • Genre:
  • Pages in Document:
    2 pdf pages
  • Volume:
    60
  • Issue:
    40
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:b615ac63bd75563c606f7ca6838c0e6b4c24eab3c8c7facf2499dbe503af966789241b9ffa579460b184334fb80dc72e44c64e1a20bb4179633afe0e6123881e
  • Download URL:
  • File Type:
    Filetype[PDF - 64.63 KB ]
File Language:
English
ON THIS PAGE

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.